PETACH TIKVA, Israel, March 5, 2015 /PRNewswire/ --
OWC Pharmaceutical Research Corp's (OTCQB: OWCP) wholly owned subsidiary One World Cannabis Ltd. ("the Company"), an Israeli research and development (R&D) company focused on cannabis-based products and treatments, today announced that it would be a senior presenter at the "Medical Cannabis and Cannabinoids" Conference organized by the Czech Republic Ministry on March 4-7, 2015.
The Medical Cannabis and Cannabinoids conference is designed to assist Czech health care professionals, including doctors, nurses and other medical staff, better understand medical cannabis and cannabinoids. Dr. Yehuda Baruch, One World Cannabis Director of Research and Regulatory Affairs, is hosting four sessions discussing the human endocannabinoid system and the effects of various strains of medical cannabis in the treatment of medical symptoms, as well as dosing concerns like how to start, how long, how and when to stop.
Dr. Tomáš Zábranský, an advisor on drug policy to the Czech Prime Minister and one of the Conference organizers: "Yehuda [Dr. Baruch] is the father and mother of the Czech Republic education programs on medical cannabis for the medical staff. This is the kick-off and he [Dr. Baruch] was extremely helpful in all the preparations of the Conference."
Prior to joining the Company, Dr. Yehuda Baruch served as Head of the Israeli Ministry of Health's Medical Cannabis Program from 2003 through 2013, where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage.
The Company's Research Division, headed by Dr. Baruch, will be focused on developing and conducting studies designed to produce new cannabis-based products for the treatment of various diseases and conditions. In addition to the R&D work, the Company's Consulting Division provides expert assistance to government officials and regulatory agencies in establishing the infrastructure necessary for the safe care and management of patents using medical cannabis.
Dr. Baruch has extensive experience in researching medical cannabis - most notably for its effect on PTSD. From 2004 until recently, he served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel. Prior to that, he was the Director of Israel's Ministry of Health medical management division, and Director General of Be'er Yakov Mental Health Center. He has taught at Ben-Gurion University of the Negev and Tel Aviv University's Sackler School of Medicine.
Ziv Turner, CEO at One World Cannabis, commented: "I firmly believe that Dr. Baruch's unique experience will further establish One World Cannabis as a leading organization in the medical-cannabis field - both in research and development and in regulatory consultant services to international entities."
About One World Cannabis Ltd.
One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
This press release contains statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," "anticipates" or other similar words or expressions. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. These forward-looking statements are subject to various risks and uncertainties, not all of which are known to the Company and many of which are beyond the Company's control, which could cause actual results to differ materially from such statements. These risks and uncertainties are described in greater detail in OWC Pharmaceutical Research Corp.'s filings with the Securities and Exchange Commission (the "Commission"), including, and without limitation, its annual and periodic reports and other documents filed with the Commission. Unless legally required, OWC Pharmaceutical Research Corp. disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE OWC Pharmaceutical Research Corp.